legend biotech

legend biotech

NASDAQ:LEGN

Chart

Detailed Quote

Legend Biotech is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy is for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from North America.

Featured Articles and Interviews
Double helix DNA with word "ETFs" and biotech stock tickers.

5 Small-cap Biotech ETFs to Watch in 2026

Press Releases

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors

Legend Biotech Corporation Announces Pricing of Public Offering

Legend Biotech Corporation Announces Proposed Public Offering 

The Conversation (0)